CompanyAGENNasdaqLexington, MA

Agenus Inc.

Agenus is a clinical-stage immuno-oncology company developing antibody-based programs to activate immunity and overcome tumor immune evasion.

SEC EDGAR ClinicalTrials.gov

6-KSep 10Latest SEC filing, period to Sep 10

Aug 18Latest story

August 2026

Agenus subsidiary amends Ocean 1181 loan, extends maturity to 2029

Aug 18PartnershipAgenus Inc.

Agenus grants CEO Garo Armen a special performance stock option award

Aug 12PeopleAgenus Inc.

Agenus posts results for zalifrelimab plus balstilimab trial in advanced cervical cancer

Aug 11Trial updateAgenus Inc.balstilimab

Agenus advances Phase 3 ROBBIN trial in colon cancer, backed by July financing

Aug 6Quarterly updateAgenus Inc.

July 2026

Dana-Farber registers Phase 2 trial of Agenus drugs in early rectal cancer

Jul 30Trial updateAgenus Inc.balstilimab

Agenus secures up to $340 million to fund Phase 3 ROBBIN trial in MSS colon cancer

Jul 13Clinical readoutAgenus Inc.

Agenus extends 2015 notes and warrant terms, adds new warrants for noteholders

Jul 6PartnershipAgenus Inc.